Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463032 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
A Phase 2 study, sponsored by GTx.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT02463032 is a Phase 2 study that has completed, run by GTx. The registered enrollment target is 136 participants.
The verdict
NCT02463032, a Phase 2 study, has completed, sponsored by GTx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.
Interventions
- DRUG GTx-024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2015-08 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02463032
The ClinicalTrials.gov registry entry for NCT02463032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GTx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTx-024 is the first listed.
NCT02463032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02463032 about?
NCT02463032 is a clinical study titled "Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer". The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.
What is the current status of trial NCT02463032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2015-08. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02463032?
The interventions under investigation include: GTx-024 (DRUG).
Who is sponsoring clinical trial NCT02463032?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.